Aventis Rabies Ad Cited By FDA For Lack Of Risk Information
This article was originally published in The Pink Sheet Daily
Executive Summary
A poster for Imovax and Imogam should be discontinued because it does not mention adverse events, CBER says. The ad also implies that other products are not available, the agency’s letter states.